Concepedia

Publication | Closed Access

Phase I Study of Bryostatin 1: Assessment of Interleukin 6 and Tumor Necrosis Factor   Induction In Vivo

DOI

187

Citations

0

References

1993

Year

P. A. Philip, Daniel Rea, P. Thavasu, J. Carmichael, N Stuart, Helaine Rockett, Dennis Talbot, Trivadi S. Ganesan, George R. Pettit, Frances R. Balkwill,
JNCI Journal of the National Cancer Institute

Abstract

The recommended dosage of bryostatin 1 for phase II studies is 25 micrograms/m2 by intravenous infusion for 1 hour once a week for 3 weeks, with no treatment in the 4th week. IL-6 and TNF-alpha plasma concentrations may be useful in monitoring biological activity of bryostatin 1. Future studies should explore use of this drug with other conventional immune modulators and conventional cytotoxic drugs.